Compare ASUR & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | BNR |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.4M | 179.7M |
| IPO Year | 1996 | 2019 |
| Metric | ASUR | BNR |
|---|---|---|
| Price | $8.79 | $8.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 83.9K | 17.5K |
| Earning Date | 04-30-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $88,952,000.00 | N/A |
| Revenue This Year | $16.33 | $111.65 |
| Revenue Next Year | $9.20 | N/A |
| P/E Ratio | $433.50 | ★ N/A |
| Revenue Growth | ★ 63.39 | N/A |
| 52 Week Low | $6.80 | $3.06 |
| 52 Week High | $11.47 | $41.72 |
| Indicator | ASUR | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 28.99 |
| Support Level | $7.91 | $8.04 |
| Resistance Level | $8.91 | $9.70 |
| Average True Range (ATR) | 0.38 | 1.17 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 17.36 | 7.02 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.